[Form 4] BRISTOL MYERS SQUIBB CO Insider Trading Activity
Phyllis R. Yale, a director of Bristol-Myers Squibb Company (BMY), reported a transaction dated 09/30/2025 on a Form 4. The filing shows acquisition of 776.053 Deferred Share Units which will convert to shares of common stock upon settlement. After this transaction the reporting person beneficially owned 37,734.687 shares, a total that the filing says includes deferred compensation and dividends reinvested. The reported price for the deferred units is $0. The Form 4 is signed by an attorney-in-fact on behalf of Ms. Yale and dated 10/02/2025.
Phyllis R. Yale, una direttrice della Bristol-Myers Squibb Company (BMY), ha riportato una transazione datata 30/09/2025 su un Modulo 4. La pratica mostra l'acquisizione di 776.053 unità differite di azioni che si convertiranno in azioni ordinarie al momento del regolamento. Dopo questa transazione la persona segnalante detiene beneficiariamente 37.734,687 azioni, un totale che la pratica indica include compensazione differita e dividendi reinvestiti. Il prezzo riportato per le unità differite è di $0. Il Modulo 4 è firmato da un procuratore in nome della signora Yale e datato 02/10/2025.
Phyllis R. Yale, una directora de Bristol-Myers Squibb Company (BMY), informó una transacción fechada el 30/09/2025 en un Form 4. La presentación muestra la adquisición de 776.053 Unidades Diferidas de Acciones que se convertirán en acciones ordinarias al asentarse. Tras esta transacción, la persona reportante posee beneficiosamente 37.734,687 acciones, un total que la presentación dice incluye compensación diferida y dividendos reinvertidos. El precio reportado para las unidades diferidas es de $0. El Form 4 está firmado por un apoderado en nombre de la Sra. Yale y fechado 02/10/2025.
Phyllis R. Yale, Bristol-Myers Squibb Company(BMY)의 이사로서, 09/30/2025로 날짜가 기재된 거래를 Form 4에 보고했습니다. 보고서는 776.053 지연 주식단위를 취득했으며 이는 정산 시 일반주로 전환됩니다. 이 거래 이후 보고자는 37.734,687주를 실제로 소유하게 되었으며, 이는 지연 보상 및 재투자 배당이 포함됨을 포함하는 총계로 보고서에 명시되어 있습니다. 지연 단위의 보고 가격은 $0입니다. Form 4는 Yale 님을 대신하여 대리인이 서명했고 2025년 10월 2일로 기재되어 있습니다.
Phyllis R. Yale, une directrice de Bristol-Myers Squibb Company (BMY), a communiqué une opération datée du 30/09/2025 sur un formulaire 4. Le dépôt montre l'acquisition de 776 053 Unités de Shares Différées qui seront converties en actions ordinaires lors du règlement. Après cette transaction, la personne déclarant détenait de manière bénéficiaire 37 734,687 actions, un total que le dépôt indique inclut une compensation différée et des dividendes réinvestis. Le prix déclaré pour les unités différées est de $0. Le Formulaire 4 est signé par un mandataire agissant au nom de Mme Yale et daté du 02/10/2025.
Phyllis R. Yale, eine Direktorin der Bristol-Myers Squibb Company (BMY), berichtete über eine Transaktion vom 30.09.2025 auf einem Formular 4. Die Einreichung zeigt den Erwerb von 776.053 Deferred Share Units, die bei Erfüllung in Stammaktien umgewandelt werden. Nach dieser Transaktion besaß die meldepflichtige Person vinkuliert 37.734,687 Aktien, insgesamt, das die Einreichung angibt, dass verzögerte Vergütung und reinvestierte Dividenden enthalten sind. Der angegebene Preis für die Deferred Units beträgt $0. Das Formular 4 ist von einem Bevollmächtigten im Namen von Frau Yale unterzeichnet und datiert auf den 02.10.2025.
Phyllis R. Yale، مديرة في Bristol-Myers Squibb Company (BMY)، أبلغت عن صفقة مؤرخة 30/09/2025 في نموذج 4. يظهر الإبلاغ استحواذ 776.053 وحدة أسهم مؤجلة ستتحول إلى أسهم عادية عند التسوية. بعد هذه الصفقة أصبحت الشخص المبلغ ملكياً فائدة 37.734,687 سهمًا، وهو الإجمالي الذي يقول الإبلاغ أنه يشمل التعويض المؤجل والربى المعاد استثمارها. السعر المُبلغ عنه للوحدات المؤجلة هو $0. يُوقع نموذج 4 من قبل وكيل نيابةً عن السيدة Yale ومؤرخ في 02/10/2025.
Phyllis R. Yale，Bristol-Myers Squibb Company（BMY）的 董事，在一份 Form 4 上报告了日期为 2025-09-30 的交易。该申报显示取得了 776.053 份延期股单位，结算时将转换为普通股。交易后，汇报人实际拥有 37.734,687 股，与申报中所述的“延期薪酬和再投资股息包含在内”的总额一致。延期单位的申报价格为 $0。Form 4 由代表 Yale 女士的代理人签署，日期为 2025-10-02。
- Director ownership increased to 37,734.687 shares following the reported transaction
- Acquisition recorded of 776.053 Deferred Share Units that will convert to common stock upon settlement
- Disclosure includes reinvested dividends, indicating accumulated deferred compensation is captured
- None.
Insights
Director deferred-compensation units increased director stake to 37,734.687 shares.
This Form 4 records a non-derivative acquisition of 776.053 Deferred Share Units on 09/30/2025 that the filer states will convert into common stock upon settlement. The filing explicitly notes the reported beneficial ownership after the transaction is 37,734.687 shares and that this total includes deferred compensation and dividends reinvested.
The transaction is routine director compensation reporting rather than a market purchase; the Form lists a $0 price for the units. This is administrative disclosure of ownership and does not by itself state any open-market trading or change in control.
Phyllis R. Yale, una direttrice della Bristol-Myers Squibb Company (BMY), ha riportato una transazione datata 30/09/2025 su un Modulo 4. La pratica mostra l'acquisizione di 776.053 unità differite di azioni che si convertiranno in azioni ordinarie al momento del regolamento. Dopo questa transazione la persona segnalante detiene beneficiariamente 37.734,687 azioni, un totale che la pratica indica include compensazione differita e dividendi reinvestiti. Il prezzo riportato per le unità differite è di $0. Il Modulo 4 è firmato da un procuratore in nome della signora Yale e datato 02/10/2025.
Phyllis R. Yale, una directora de Bristol-Myers Squibb Company (BMY), informó una transacción fechada el 30/09/2025 en un Form 4. La presentación muestra la adquisición de 776.053 Unidades Diferidas de Acciones que se convertirán en acciones ordinarias al asentarse. Tras esta transacción, la persona reportante posee beneficiosamente 37.734,687 acciones, un total que la presentación dice incluye compensación diferida y dividendos reinvertidos. El precio reportado para las unidades diferidas es de $0. El Form 4 está firmado por un apoderado en nombre de la Sra. Yale y fechado 02/10/2025.
Phyllis R. Yale, Bristol-Myers Squibb Company(BMY)의 이사로서, 09/30/2025로 날짜가 기재된 거래를 Form 4에 보고했습니다. 보고서는 776.053 지연 주식단위를 취득했으며 이는 정산 시 일반주로 전환됩니다. 이 거래 이후 보고자는 37.734,687주를 실제로 소유하게 되었으며, 이는 지연 보상 및 재투자 배당이 포함됨을 포함하는 총계로 보고서에 명시되어 있습니다. 지연 단위의 보고 가격은 $0입니다. Form 4는 Yale 님을 대신하여 대리인이 서명했고 2025년 10월 2일로 기재되어 있습니다.
Phyllis R. Yale, une directrice de Bristol-Myers Squibb Company (BMY), a communiqué une opération datée du 30/09/2025 sur un formulaire 4. Le dépôt montre l'acquisition de 776 053 Unités de Shares Différées qui seront converties en actions ordinaires lors du règlement. Après cette transaction, la personne déclarant détenait de manière bénéficiaire 37 734,687 actions, un total que le dépôt indique inclut une compensation différée et des dividendes réinvestis. Le prix déclaré pour les unités différées est de $0. Le Formulaire 4 est signé par un mandataire agissant au nom de Mme Yale et daté du 02/10/2025.
Phyllis R. Yale, eine Direktorin der Bristol-Myers Squibb Company (BMY), berichtete über eine Transaktion vom 30.09.2025 auf einem Formular 4. Die Einreichung zeigt den Erwerb von 776.053 Deferred Share Units, die bei Erfüllung in Stammaktien umgewandelt werden. Nach dieser Transaktion besaß die meldepflichtige Person vinkuliert 37.734,687 Aktien, insgesamt, das die Einreichung angibt, dass verzögerte Vergütung und reinvestierte Dividenden enthalten sind. Der angegebene Preis für die Deferred Units beträgt $0. Das Formular 4 ist von einem Bevollmächtigten im Namen von Frau Yale unterzeichnet und datiert auf den 02.10.2025.
FAQ
What did Phyllis R. Yale report on Form 4 for BMY?
Do the Deferred Share Units convert to Bristol-Myers (BMY) common stock?
What price was reported for the Deferred Share Units?
Does the filing indicate the ownership includes other compensation?
When was the Form 4 signed and filed?
